Loading patent…
OwnerRonald PECK, Sarah Deborah CHIRNOMAS +7inventors
InventorsRonald PECK, Sarah Deborah CHIRNOMAS, Edward CHAN, Richard Walter GEDRICH, Elmer J. BERGHORN, Jr., Jeanette Toni ALICEA, Lawrence B. SNYDER, SangHyun LEE, Taavi NEKLESA
Estimating the term…
This disclosure pertains to methods of treating prostate cancer in a subject, including prostate cancer comprising at least one somatic AR tumor mutation, such as metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naïve to novel hormonal agents (NHAs), metastatic prostate cancer naïve NHAs, castrate-resistant prostate cancer naïve to NHAs, castrate-sensitive prostate cancer naïve to NHAs, metastatic castrate-resistant prostate cancer naïve to NHAs, and metastatic castrate-sensitive prostate cancer naïve to NHAs, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof.
-9. (canceled)
A method of treating prostate cancer in a subject comprising administering to the subject in need thereof a therapeutically effective amount of Compound A,
(canceled)
A method of treating prostate cancer in a subject comprising administering to the subject in need thereof:
-15. (canceled)
A method of treating prostate cancer naïve to novel hormonal agents (NHAs) in a subject comprising administering to the subject in need thereof a therapeutically effective amount of Compound A,
(canceled)
A method of treating prostate cancer naïve to novel hormonal agents (NHAs) in a subject comprising administering to the subject in need thereof:
(canceled)
-71. (canceled)
A method of treating prostate cancer having at least one somatic AR tumor mutation in a subject comprising administering to the subject in need thereof a therapeutically effective amount of Compound A,
(canceled)
A method of treating prostate cancer having at least one somatic AR tumor mutation in a subject comprising administering to the subject in need thereof:
-80. (canceled)
A method of treating prostate cancer having at least one somatic AR tumor mutation in a subject comprising administering to the subject in need thereof a therapeutically effective amount of Compound A,
(canceled)
A method of treating prostate cancer having at least one somatic AR tumor mutation in a subject comprising administering to the subject in need thereof:
-86. (canceled)
A method of treating prostate cancer naïve to novel hormonal agents (NHAs) having at least one somatic AR tumor mutation in a subject comprising administering to the subject in need thereof a therapeutically effective amount of Compound A,
(canceled)
A method of treating prostate cancer naïve to novel hormonal agents (NHAs) having at least one somatic AR tumor mutation in a subject comprising administering to the subject in need thereof:
(canceled)
-95. (canceled)
-113. (canceled)
Dependencies are inferred from the claim text.